Kardigan Tech Stack
Cardiovascular drug discovery using patient-matched clinical trial data
Kardigan is a cardiovascular biotech company founded in 2023 pursuing functional disease modification rather than symptom management. The hiring mix—dominated by clinical ops, research, and data roles at the director/senior level—reflects a company scaling from discovery into human trials; notably absent are typical early-stage bench chemists, suggesting they're outsourcing synthesis and focusing internally on trial design, patient stratification, and manufacturing oversight. Active projects span engineered tissue models, high-throughput mechanistic screening, and oligonucleotide/small-molecule manufacturing implementation, indicating a multi-modality pipeline entering late-phase development.
Tech Stack 11 technologies
What Kardigan Is Building
◆Challenges
- Lack of physiologically relevant in vitro models
- Implementing new manufacturing technologies
- Ensuring inspection readiness
- Preparing for ipo
- Optimizing company valuation
- Building investor relations function
- Managing regulatory submissions
- Scaling it operations for growth
- Maintaining compliance with infrastructure standards
- Implementing contract lifecycle management system
▲Active Projects
- Cardiovascular clinical study
- Engineered heart tissue models for cardiovascular disease
- High-throughput multi-well mechanistic assessments in vitro
- Comprehensive investor relations program
- Standardized trial management process implementation
- Oligonucleotide manufacturing implementation
- Small molecule manufacturing implementation
- Contract lifecycle management system implementation
- Late phase nda portfolio development
- Develop biometrics function and strategy
Hiring Activity
Department
Seniority
Notable leadership hires: Clinical Operations Program Lead, Portfolio Director, Head of Development Services, Head of Data Analytics, Clinical Trial Lead
